Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

85.36 -3.54 (-3.98%)
Streaming Delayed Price Updated: 2:54 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 370,133
Open 88.45
Bid (Size) 85.26 (1)
Ask (Size) 85.37 (1)
Prev. Close 88.90
Today's Range 84.93 - 89.89
52wk Range 43.89 - 101.00
Shares Outstanding 61,232,297
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Decoding 6 Analyst Evaluations For Blueprint Medicines
Via Benzinga
(BPMC) - Analyzing Blueprint Medicines's Short Interest
Via Benzinga

Performance

YTD
-6.27%
-6.27%
1 Month
-2.97%
-2.97%
3 Month
+7.13%
+7.13%
6 Month
+85.32%
+85.32%
1 Year
+76.15%
+76.15%

More News

Read More
Blueprint Medicines Corp. (NASDAQ: BPMC) Climbs to New 52-Week High
Via Investor Brand Network
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For February 15, 2024
Via Benzinga
Blueprint Medicines's Earnings Outlook
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Blueprint Medicines
Via Benzinga
Peeling Back The Layers: Exploring Blueprint Medicines Through Analyst Insights
Via Benzinga
Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing.
Via Investor's Business Daily
Raymond James Maintains Strong Buy Rating for Blueprint Medicines: Here's What You Need To Know
Via Benzinga
Chart Of The Day: Does Blueprint Medicines Have A Blueprint For Success?
Via Talk Markets
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
The Latest Analyst Ratings for Blueprint Medicines
Via Benzinga
Needham Maintains Buy Rating for Blueprint Medicines: Here's What You Need To Know
Via Benzinga
Barclays Maintains Equal-Weight Rating for Blueprint Medicines: Here's What You Need To Know
Via Benzinga
Why Blueprint Medicines Stock Soared Today
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Blueprint Medicines Corp. (NASDAQ: BPMC) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
Blueprint Medicines's Earnings: A Preview
Via Benzinga
Unpacking Blueprint Medicines' Ayvakit's Bright Future: Insights From Latest Physician Survey On Sales Predictions
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
What 15 Analyst Ratings Have To Say About Blueprint Medicines
Via Benzinga
Why Shares of Blueprint Medicines Are Falling Wednesday
Via The Motley Fool
Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.